Skip to main content

Table 3 The rate of drug discontinuation and its reasons

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

 

ABT (n = 21)

JAKi (n = 21)

Lack of effect, n (%)

9 (42.9)

4 (19.0)

Adverse events, n (%)

4 (19.0)

5 (23.8)

Infections, n (%)

0 (0.0)

2 (9.5)

Lung involvement, n (%)

0 (0.0)

1 (4.8)

Leukopenia, n (%)

0 (0.0)

1 (4.8)

Neoplasia n (%)

0 (0.0)

1 (4.8)

Others, n (%)

4 (19.0)

0 (0.0)

  1. Data are presented as number of patients (%)
  2. ABT: abatacept; JAKi: Janus kinase inhibitors; Infections: herpes zosters and herpes labialis; Others: skin rash, drop in the blood pressure, dizziness, chronic obstructive pulmonary disease
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us